Clinical trials: Frown Lines
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
- Trial name
- NCT03004248
- Testing
- Botulinum Toxins, Type A
- Where
- 61 sites in United States, Canada
- Volunteers
- 2,691 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT03440671
- Testing
- Hutox Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Huons Co., Ltd.
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- EV-002 (NCT02334436)
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT04281095
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Glabellar Frown Lines
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label…
- Trial name
- NCT04143815
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Healthy
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relaxation of the injected muscle.
- Trial name
- NCT00694148
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.
- Trial name
- NCT01391312
- Testing
- botulinum toxin Type A
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
The Treatment of Glabellar Frown Lines
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
- Trial name
- NCT02096081
- Testing
- IncobotulinumtoxinA, OnabotulinumtoxinA
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar…
- Trial name
- NCT02236312
- Testing
- Botulinum Toxin Type A
- Where
- 8 sites in United States
- Volunteers
- 359 people
- Sponsor
- Galderma R&D
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
The study objective was to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770029
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESSIII (NCT03985982)
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- Croma-Pharma GmbH